DOCSLIB.ORG

JIA Voice of the Patient Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
JIA Voice of the Patient Report Externally-led Juvenile Idiopathic Arthritis Patient-Focused Drug Development Meeting Report V 1.3 10/7/191 Table of Contents The Arthritis Foundation and CARRA 3 Purpose of the PFDD Project 4 History of JIA Treatment and Current State of the Art 5 Overview/Introduction of the Meeting and Pre-Meeting Content 9 Topic I: JIA Symptoms and Daily Impacts That Matter Most to Patients 12 Topic 2: Patients’ Perspectives on Current Approaches to Treating JIA 18 Topic 3: Patients’ Perspectives on Clinical Trial Design 26 FDA Engagement . 32 Treatment Horizon: Challenges and Opportunities 33 Arthritis Foundation/CARRA Research and Patient Engagement Efforts 34 Appendices Appendix 1 Project Team Appendix 2 Pre-Meeting Survey Results Appendix 3 Focus Group Summary Appendix 5 In-Meeting Polling Question Appendix 4 Speaker and Panelist Biographies Appendix 6 Meeting Transcript 2 Externally-led Juvenile Idiopathic Arthritis Patient-Focused Drug Development Meeting Report The Food and Drug Administration (FDA) seeks to understand and reflect the perspectives of patients and caregivers in the drug development process Over the past six years, the FDA has conducted 25 internally- led patient-focused drug development (PFDD) meetings on various conditions to systematically gather critical input regarding the issues and challenges that affect patients’ treatment needs, choices, compliance and quality of life. Recognizing that a significant number of diseases still needed to be addressed, the FDA issued a call for partners to conduct externally-led PFDD meetings to collaborate on these critical information-gathering initiatives The Arthritis Foundation answered that call in March 2017 hosting an Osteoarthritis externally-led PFDD meeting Then again in August 2018, the Arthritis Foundation partnered with the Childhood Arthritis and Rheumatology Research Alliance (CARRA) to co-host the externally-led PFDD meeting about Juvenile Idiopathic Arthritis. The Arthritis Foundation and CARRA are proud to engage with the FDA in this initiative to provide patient input regarding juvenile idiopathic arthritis (JIA) The Arthritis Foundation and CARRA For more than 70 years, the Arthritis Foundation has been the leading patient advocacy group for adults and children living with arthritis, the nation’s leading cause of disability. A core tenet of the Foundation’s mission is accelerating groundbreaking research through financial support and strategic partnerships. This mission served as the catalyst for the Foundation’s collaboration with the Childhood Arthritis and Rheumatology Research Alliance (CARRA) “Participation in research is the path to a cure and the Arthritis Foundation is committed to bringing new opportunities for researchers, clinicians, patients and families to actively pursue better treatments with us.” – Ann Palmer, Arthritis Foundation Established in 2002, CARRA is a pediatric rheumatology research network whose mission is to conduct collaborative research to prevent, treat and cure pediatric rheumatic diseases. CARRA’s research network includes almost all the pediatric rheumatology centers across the U.S. and Canada. Members include clinicians, researchers and research coo rdinators The Arthritis Foundation has funded CARRA’s infrastructure and operations since its inception and the organizations have been collaborative partners for more than a decade. In 2015, the partnership evolved to a more strategic one that aligns scientific agendas; expands research about the impact, unmet needs and treatment of pediatric rheumatic diseases; and prioritizes patients’ and families’ participation in meaningful and high-quality clinical and translational research Among recent collaborations has been an effort with the FDA to advance understanding of patient perceptions around treatment, risk/benefit analysis, and clinical trial design. A manuscript entitled “Toward Improvement in the Timely Authorization and Availability of New Medicines for Juvenile Idiopathic Arthritis: Multi-Stakeholder Perspectives” has been submitted for publication summarizing an April 2018 CARRA- and AF-sponsored meeting of FDA, European Medicines Agency (EMA), major pharmaceutical companies, clinicians, researchers, patients and parents arthritis.org | carragroup.org 3 Purpose of the PFDD Project Through its Division of Pulmonary, Allergy and Rheumatology Products, the FDA oversees drug development for rheumatic diseases including juvenile idiopathic arthritis (JIA) With the enactment of the Prescription Drug User Fee Act (PDUFA) in 1992, Congress created a mechanism for the FDA to accelerate the review and approval of innovative medicines and products based on the best available science As part of this initiative, the FDA recognizes the need to broaden patient and caregiver input to identify the critical variables, endpoints and outcomes that more accurately represent the burden of disease and the impact of available treatments. To help meet these needs, the PFDD initiative was launched in 2012 The goals of the PFDD initiative are to •Develop treatments that meaningfully address the aspects of disease most important to patients • Tailor clinical trials to reflect patient’s perspective on the benefits and harms of treatment in drug evaluation • Ensure the information and data accurately represent self-reported benefits and harms and is directly relevant to patient’s treatment needs and decisions Nikolay Nikolov, MD, Associate Director for Rheumatology, FDA Division of Pulmonary, Allergy, and Rheumatology Products, summed up the importance of PFDD meetings during his introductory comments at the Externally-led JIA PFDD Meeting “The information will help to better inform the benefits-risk assessment of new therapies, identify areas of unmet need and help drug developers and regulatory authorities, such as the FDA, design programs that are more relevant to addressing how patients feel and function.” – Nikolay Nikolov, MD, Food and Drug Administration In December 2016, the 21st Century Cures Act was enacted to accelerate the translation of scientific discovery into FDA-approved treatments, foster interdisciplinary and cross-functional collaboration, and integrate patient insights into the regulatory review process. The law builds on efforts of the FDA to include patient perspectives into the drug and medical product development process Through their PFDD and 21st Century Cures Act efforts, one goal of the FDA is to bring safe and innovative therapies to arthritis patients faster This will help minimize •Joint damage, disability and other barriers to optimal health-related quality of life. •Disruptions to educational and career experiences and opportunities •The negative impact on social, psychosocial and family dynamics 4 History of JIA Treatment and Current State of the Art More than 100 years ago when rheumatic diseases were first diagnosed in children, significant joint pain, loss of function, and deformity were the norm Aspirin and glucocorticoids were the only drugs regularly used However, the side effects of extended steroid use included increased osteoporosis risk, abnormal skeletal growth, obesity and increased infection risk. By the1970s, nonsteroidal anti- inflammatories became available. Older treatments, such as gold and penicillamine, were sometimes used despite a high toxicity rates with little benefit. It wasn’t until the 1980s and the availability of the disease-modifying antirheumatic drug (DMARD) methotrexate that an era of disease suppression with significant improvements in outcomes commenced. This paved the way for more aggressive use of DMARDs in JIA Biologic response modifiers, or biologics, became available in the late 1990s. These powerful and game-changing therapies for inflammatory arthritis specifically target specific components of the immune system. With small-molecule targeted therapies now available in adults, the JIA community is awaiting the first small-molecule indications for children. Table 1. Biologics and Small-Molecule Targeted Therapies for Arthritis TNF Inhibitors IL-1 Inhibitors •Infliximab (Remicade) •Anakinra (Kineret)** •Etanercept (Enbrel)* •Canakinumab (Ilaris)* •Adalimumab (Humira)* •Rilonacept (Arcalyst) •Golimumab (Simponi)** IL-17 Inhibitors •Certolizumab (Cimzia)** •Secukinumab (Cosentyx)** Inhibitor of CD28-B7 •Ixekizumab (Taltz) (T cell co-stimulation signal) IL-12/23 Inhibitor •Abatacept (Orencia)* •Ustekinumab (Stelara) IL-6 Inhibitors JAK Inhibitors [Small Molecule] •Tocilizumab (Actemra)* •Tofacitinib (Xeljanz)** •Sarilumab (Kevzara)** •Baricitinib (Olumiant)** B cell Inhibitor Phosphodiesterase Inhibitor •Rituximab (Rituxan) [Small Molecule] •Apremilast (Otezla) *FDA Approved for JIA. **Currently in clinical trial for FDA approval in JIA. 5 Table 2. JIA Disease Subtypes JIA Subtype Characteristics Oligoarthritis-persistent • Fewer than five affected joints with no additional joint involvement after the first six months • Highest risk for uveitis that may progress to glaucoma, cataracts and possibly blindness • Usually affects young girls Oligoarthritis-extended • Initially involves fewer than five joints for the first six months and then disease progresses to additional joints •High risk for uveitis •Usually affects young girls Polyarthritis RF negative • Involves five or more joints (small and large) within the first six months •Symmetric joint involvement of many joints is common •Rheumatoid factor blood test is negative •Occurs early in childhood •More common in girls Polyarthritis RF positive • Involves five or more joints
Load more

Recommended publications
  • Septic Arthritis of the Sternoclavicular Joint
    J Am Board Fam Med: first published as 10.3122/jabfm.2012.06.110196 on 7 November 2012. Downloaded from BRIEF REPORT Septic Arthritis of the Sternoclavicular Joint Jason Womack, MD Septic arthritis is a medical emergency that requires immediate action to prevent significant morbidity and mortality. The sternoclavicular joint may have a more insidious onset than septic arthritis at other sites. A high index of suspicion and judicious use of laboratory and radiologic evaluation can help so- lidify this diagnosis. The sternoclavicular joint is likely to become infected in the immunocompromised patient or the patient who uses intravenous drugs, but sternoclavicular joint arthritis in the former is uncommon. This case series describes the course of 2 immunocompetent patients who were treated conservatively for septic arthritis of the sternoclavicular joint. (J Am Board Fam Med 2012;25: 908–912.) Keywords: Case Reports, Septic Arthritis, Sternoclavicular Joint Case 1 of admission, he continued to complain of left cla- A 50-year-old man presented to his primary care vicular pain, and the course of prednisone failed to physician with a 1-week history of nausea, vomit- provide any pain relief. The patient denied any ing, and diarrhea. His medical history was signifi- current fevers or chills. He was afebrile, and exam- cant for 1 episode of pseudo-gout. He had no ination revealed a swollen and tender left sterno- chronic medical illnesses. He was noted to have a clavicular (SC) joint. The prostate was normal in heart rate of 60 beats per minute and a blood size and texture and was not tender during palpa- pressure of 94/58 mm Hg.
    [Show full text]
  • Approach to Polyarthritis for the Primary Care Physician
    24 Osteopathic Family Physician (2018) 24 - 31 Osteopathic Family Physician | Volume 10, No. 5 | September / October, 2018 REVIEW ARTICLE Approach to Polyarthritis for the Primary Care Physician Arielle Freilich, DO, PGY2 & Helaine Larsen, DO Good Samaritan Hospital Medical Center, West Islip, New York KEYWORDS: Complaints of joint pain are commonly seen in clinical practice. Primary care physicians are frequently the frst practitioners to work up these complaints. Polyarthritis can be seen in a multitude of diseases. It Polyarthritis can be a challenging diagnostic process. In this article, we review the approach to diagnosing polyarthritis Synovitis joint pain in the primary care setting. Starting with history and physical, we outline the defning characteristics of various causes of arthralgia. We discuss the use of certain laboratory studies including Joint Pain sedimentation rate, antinuclear antibody, and rheumatoid factor. Aspiration of synovial fuid is often required for diagnosis, and we discuss the interpretation of possible results. Primary care physicians can Rheumatic Disease initiate the evaluation of polyarthralgia, and this article outlines a diagnostic approach. Rheumatology INTRODUCTION PATIENT HISTORY Polyarticular joint pain is a common complaint seen Although laboratory studies can shed much light on a possible diagnosis, a in primary care practices. The diferential diagnosis detailed history and physical examination remain crucial in the evaluation is extensive, thus making the diagnostic process of polyarticular symptoms. The vast diferential for polyarticular pain can difcult. A comprehensive history and physical exam be greatly narrowed using a thorough history. can help point towards the more likely etiology of the complaint. The physician must frst ensure that there are no symptoms pointing towards a more serious Emergencies diagnosis, which may require urgent management or During the initial evaluation, the physician must frst exclude any life- referral.
    [Show full text]
  • Burden of Childhood-Onset Arthritis Pedi- Atric Rheumatology 2010, 8:20
    Moorthy et al. Pediatric Rheumatology 2010, 8:20 http://www.ped-rheum.com/content/8/1/20 REVIEW Open Access BurdenReview of childhood-onset arthritis Lakshmi N Moorthy*1, Margaret GE Peterson2, Afton L Hassett3 and Thomas JA Lehman2,4 Abstract Juvenile arthritis comprises a variety of chronic inflammatory diseases causing erosive arthritis in children, often progressing to disability. These children experience functional impairment due to joint and back pain, heel pain, swelling of joints and morning stiffness, contractures, pain, and anterior uveitis leading to blindness. As children who have juvenile arthritis reach adulthood, they face possible continuing disease activity, medication-associated morbidity, and life-long disability and risk for emotional and social dysfunction. In this article we will review the burden of juvenile arthritis for the patient and society and focus on the following areas: patient disability; visual outcome; other medical complications; physical activity; impact on HRQOL; emotional impact; pain and coping; ambulatory visits, hospitalizations and mortality; economic impact; burden on caregivers; transition issues; educational occupational outcomes, and sexuality. The extent of impact on the various aspects of the patients', families' and society's functioning is clear from the existing literature. Juvenile arthritis imposes a significant burden on different spheres of the patients', caregivers' and family's life. In addition, it imposes a societal burden of significant health care costs and utilization. Juvenile arthritis affects health-related quality of life, physical function and visual outcome of children and impacts functioning in school and home. Effective, well-designed and appropriately tailored interventions are required to improve transitioning to adult care, encourage future vocation/occupation, enhance school function and minimize burden on costs.
    [Show full text]
  • Study Guide Medical Terminology by Thea Liza Batan About the Author
    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
    [Show full text]
  • Journal of Arthritis DOI: 10.4172/2167-7921.1000102 ISSN: 2167-7921
    al of Arth rn ri u ti o s J García-Arias et al., J Arthritis 2012, 1:1 Journal of Arthritis DOI: 10.4172/2167-7921.1000102 ISSN: 2167-7921 Research Article Open Access Septic Arthritis and Tuberculosis Arthritis Miriam García-Arias, Silvia Pérez-Esteban and Santos Castañeda* Rheumatology Unit, La Princesa Universitary Hospital, Madrid, Spain Abstract Septic arthritis is an important medical emergency, with high morbidity and mortality. We review the changing epidemiology of infectious arthritis, which incidence seems to be increasing due to several factors. We discuss various different risk factors for development of septic arthritis and examine host factors, bacterial proteins and enzymes described to be essential for the pathogenesis of septic arthritis. Diagnosis of disease should be making by an experienced clinician and it is almost based on clinical symptoms, a detailed history, a careful examination and test results. Treatment of septic arthritis should include prompt removal of purulent synovial fluid and needle aspiration. There is little evidence on which to base the choice and duration of antibiotic therapy, but treatment should be based on the presence of risk factors and the likelihood of the organism involved, patient’s age and results of Gram’s stain. Furthermore, we revised joint and bone infections due to tuberculosis and atypical mycobacteria, with a special mention of tuberculosis associated with anti-TNFα and biologic agents. Keywords: Septic arthritis; Tuberculosis arthritis; Antibiotic therapy; Several factors have contributed to the increase in the incidence Anti-TNFα; Immunosuppression of septic arthritis in recent years, such as increased orthopedic- related infections, an aging population and an increase in the use of Joint and bone infections are uncommon, but are true rheumatologic immunosuppressive therapy [4].
    [Show full text]
  • Ankylosing Spondylitis
    Henry Ford Hosp Med Journal Vol 27, No 1, 1979 Ankylosing Spondylitis Carlina V. jimenea, MD* Spondyllitisi , in the broad sense, means arthritis or inflam­ continuous bone." From these observations, Connor de­ mation of the spine. The term is derived from the Greek duced that the person "must have been immovable, that he words "spondylos," meaning vertebra, "-itis" for inflamma­ could neither bend nor stretch himself out, rise up, nor lie tion, and "ankylos," meaning bent or crooked. Ankylosing down norturn upon his side." Such a skeleton might appear spondylitis, therefore, is a chronic inflammatory disease of as illustrated (Figures 1 and 2).* the spine resulting in progressive stiffening with fusion ofthe various anatomical elements. Other early descriptions were reported by Wilks (1858), von Thaden (1863), Blezinger (1864), Bradhurst (1866), Virchow (1869), Harrison (1870), Flagg (1876) and Strum- History pell (1884).^ The most complete clinical description ofthe Ankylosing spondylitis has plagued man since antiquity. disease, however, is credited to von Bechterew, who in Ruffer and Reitti described the skeleton of a man living 1893 described what he thought was a new neurological during the third dynasty (2980 to 2900 B.C.) whose spinal disease characterized by stiffness ofall orpart of the spine, column, presumably in its entire length, was diseased and paresis of the muscles of the back, neck and extremities. transformed into a solid block because of new bone forma­ Later in 1897, Strumpell reported a group of cases with tion in the longitudinal ligaments. A skeleton found in progressive ankylosis ofthe spine and hip joints. In 1898, Nordpfalzdated (bytomb gifts enclosed)about400 B.C., was Marie described six cases characterized by an ascending reported by Arnold^ as showing similar changes.
    [Show full text]
  • Conditions Related to Inflammatory Arthritis
    Conditions Related to Inflammatory Arthritis There are many conditions related to inflammatory arthritis. Some exhibit symptoms similar to those of inflammatory arthritis, some are autoimmune disorders that result from inflammatory arthritis, and some occur in conjunction with inflammatory arthritis. Related conditions are listed for information purposes only. • Adhesive capsulitis – also known as “frozen shoulder,” the connective tissue surrounding the joint becomes stiff and inflamed causing extreme pain and greatly restricting movement. • Adult onset Still’s disease – a form of arthritis characterized by high spiking fevers and a salmon- colored rash. Still’s disease is more common in children. • Caplan’s syndrome – an inflammation and scarring of the lungs in people with rheumatoid arthritis who have exposure to coal dust, as in a mine. • Celiac disease – an autoimmune disorder of the small intestine that causes malabsorption of nutrients and can eventually cause osteopenia or osteoporosis. • Dermatomyositis – a connective tissue disease characterized by inflammation of the muscles and the skin. The condition is believed to be caused either by viral infection or an autoimmune reaction. • Diabetic finger sclerosis – a complication of diabetes, causing a hardening of the skin and connective tissue in the fingers, thus causing stiffness. • Duchenne muscular dystrophy – one of the most prevalent types of muscular dystrophy, characterized by rapid muscle degeneration. • Dupuytren’s contracture – an abnormal thickening of tissues in the palm and fingers that can cause the fingers to curl. • Eosinophilic fasciitis (Shulman’s syndrome) – a condition in which the muscle tissue underneath the skin becomes swollen and thick. People with eosinophilic fasciitis have a buildup of eosinophils—a type of white blood cell—in the affected tissue.
    [Show full text]
  • Still Disease
    University of Massachusetts Medical School eScholarship@UMMS Open Access Articles Open Access Publications by UMMS Authors 2019-02-17 Still Disease Juhi Bhargava Medstar Washington Hospital Center Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Immune System Diseases Commons, Musculoskeletal Diseases Commons, Pathological Conditions, Signs and Symptoms Commons, Skin and Connective Tissue Diseases Commons, and the Viruses Commons Repository Citation Bhargava J, Panginikkod S. (2019). Still Disease. Open Access Articles. Retrieved from https://escholarship.umassmed.edu/oapubs/3764 Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Still Disease Juhi Bhargava; Sreelakshmi Panginikkod. Author Information Last Update: February 17, 2019. Go to: Introduction Adult Onset Still's Disease (AOSD) is a rare systemic inflammatory disorder characterized by daily fever, inflammatory polyarthritis, and a transient salmon-pink maculopapular rash. AOSD is alternatively known as systemic onset juvenile idiopathic arthritis. Even though there is no specific diagnostic test, a serum ferritin level more than 1000ng/ml is common in AOSD. Go to: Etiology The etiology of AOSD is unknown. The hypothesis remains that AOSD is a reactive syndrome in which various infectious agents may act as triggers in a genetically predisposed host. Both genetic factors and a variety of viruses, bacteria like Yersinia enterocolitica and Mycoplasma pneumonia and other infectious factors have been suggested as important[1][2].
    [Show full text]
  • The Relationship Between Synovial Inflammation in Whole-Organ Magnetic Resonance Imaging Score and Traditional Chinese Medicine
    Yu-guo G, Hong J. The Relationship between Synovial Inflammation in Whole-Organ Magnetic Resonance Imaging Score and Traditional Chinese Medicine Syndrome Pattern of Osteoarthritis in the Knee. J Orthopedics & Orthopedic Surg. 2020;1(2):4-9 Research Article Open Access The Relationship between Synovial Inflammation in Whole-Organ Magnetic Resonance Imaging Score and Traditional Chinese Medicine Syndrome Pattern of Osteoarthritis in the Knee Gu Yu-guo, Jiang Hong* Department of Orthopaedics and Traumatology, Suzhou TCM Hospital, in affiliation with Nanjing University of Chinese Medicine, Suzhou, China Article Info Abstract Article Notes Purpose: The aim of this study was to guide the quantitative analysis Received: February 04, 2020 Accepted:June 19, 2020 of Traditional Chinese Medicine (TCM) syndromes by the measurement of magnetic resonance. *Correspondence: *Dr. Jiang Hong, Department of Orthopaedics and Traumatology, Methods: A total of 213 patients with knee osteoarthritis were selected Suzhou TCM Hospital, in affiliation with Nanjing University of Chinese for TCM dialectical classification, and their MRI images were scored on Whole- Medicine, Suzhou, China; Telephone No: + 86 138 6255 7621; Email: Organ Magnetic Resonance Imaging Score (WORMS) to evaluate the correlation [email protected]. between severity of synovitis and TCM syndrome types in the scores. ©2020 Hong J. This article is distributed under the terms of the Results: Among the 213 patients, 25 were Anemofrigid-damp arthralgia Creative Commons Attribution 4.0 International License. syndrome (accounting for 11.7%), 84 were Pyretic arthralgia syndrome (39.4%), 43 were Blood stasis syndrome (20.2%), and 61 were Liver and kidney Keywords: vitality deficiency syndrome (28.6%).
    [Show full text]
  • Differential Diagnosis of Juvenile Idiopathic Arthritis
    pISSN: 2093-940X, eISSN: 2233-4718 Journal of Rheumatic Diseases Vol. 24, No. 3, June, 2017 https://doi.org/10.4078/jrd.2017.24.3.131 Review Article Differential Diagnosis of Juvenile Idiopathic Arthritis Young Dae Kim1, Alan V Job2, Woojin Cho2,3 1Department of Pediatrics, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea, 2Department of Orthopaedic Surgery, Albert Einstein College of Medicine, 3Department of Orthopaedic Surgery, Montefiore Medical Center, New York, USA Juvenile idiopathic arthritis (JIA) is a broad spectrum of disease defined by the presence of arthritis of unknown etiology, lasting more than six weeks duration, and occurring in children less than 16 years of age. JIA encompasses several disease categories, each with distinct clinical manifestations, laboratory findings, genetic backgrounds, and pathogenesis. JIA is classified into sev- en subtypes by the International League of Associations for Rheumatology: systemic, oligoarticular, polyarticular with and with- out rheumatoid factor, enthesitis-related arthritis, psoriatic arthritis, and undifferentiated arthritis. Diagnosis of the precise sub- type is an important requirement for management and research. JIA is a common chronic rheumatic disease in children and is an important cause of acute and chronic disability. Arthritis or arthritis-like symptoms may be present in many other conditions. Therefore, it is important to consider differential diagnoses for JIA that include infections, other connective tissue diseases, and malignancies. Leukemia and septic arthritis are the most important diseases that can be mistaken for JIA. The aim of this review is to provide a summary of the subtypes and differential diagnoses of JIA. (J Rheum Dis 2017;24:131-137) Key Words.
    [Show full text]
  • Juvenile Idiopathic Arthritis Associated Uveitis
    children Review Juvenile Idiopathic Arthritis Associated Uveitis Emil Carlsson 1,*, Michael W. Beresford 1,2,3, Athimalaipet V. Ramanan 4, Andrew D. Dick 5,6,7 and Christian M. Hedrich 1,2,3,* 1 Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L14 5AB, UK; [email protected] 2 Department of Rheumatology, Alder Hey Children’s NHS Foundation Trust Hospital, Liverpool L14 5AB, UK 3 National Institute for Health Research Alder Hey Clinical Research Facility, Alder Hey Children’s NHS Foundation Trust Hospital, Liverpool L14 5AB, UK 4 Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol BS2 8DZ, UK; [email protected] 5 Translational Health Sciences, University of Bristol, Bristol BS2 8DZ, UK; [email protected] 6 UCL Institute of Ophthalmology, London EC1V 9EL, UK 7 NIHR Biomedical Research Centre, Moorfields Eye Hospital, London EC1V 2PD, UK * Correspondence: [email protected] (E.C.); [email protected] (C.M.H.); Tel.: +44-151-228-4811 (ext. 2690) (E.C.); +44-151-252-5849 (C.M.H.) Abstract: Juvenile idiopathic arthritis (JIA) is the most common childhood rheumatic disease. The development of associated uveitis represents a significant risk for serious complications, including permanent loss of vision. Initiation of early treatment is important for controlling JIA-uveitis, but the disease can appear asymptomatically, making frequent screening procedures necessary for patients at risk. As our understanding of pathogenic drivers is currently incomplete, it is difficult to assess which JIA patients are at risk of developing uveitis.
    [Show full text]
  • A Rheumatologist Needs to Know About the Adult with Juvenile Idiopathic Arthritis
    A Rheumatologist Needs to Know About the Adult With Juvenile Idiopathic Arthritis Juvenile idiopathic arthritis (JIA) encompasses a range of distinct phenotypes. By definition, JIA includes all forms of arthritis of unknown cause that start before the 16th birthday. The most common form is oligoarticular JIA, typically starting in early childhood (before age 6) and affecting only a few large joints. Polyarticular JIA, affecting 5 joints or more, can occur at any age; older children may develop seropositive arthritis indistinguishable from adult rheumatoid arthritis. Systemic JIA (sJIA) is characterized by fevers and rash at onset of disease, though it may evolve into an afebrile chronic polyarthritis that can be resistant to therapy. Patients with sJIA, like those with adult onset Still’s disease (AOSD), are susceptible to macrophage activation syndrome, a “cytokine storm” characterized by fever, disseminated intravascular coagulation, and end organ dysfunction. Other forms of arthritis in children include psoriatic JIA and so-called “enthesitis related arthritis,” encompassing the non-psoriatic spondyloarthropathies. Approximately 50% of JIA patients will have active disease into adulthood. JIA can be accompanied by destructive chronic uveitis. In addition to joints, JIA can involve the eyes, resulting in a form of chronic scarring uveitis not seen in adult arthritis. Patients at particularly high risk are those with oligoarticular or polyarticular arthritis beginning before the age of 6 years, especially if accompanied by positive ANA at any titer. In thehighest risk group, up to 30% of children may be affected. Patients who did not develop uveitis in childhood are very unlikely to do so as adults.
    [Show full text]